<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00387088</url>
  </required_header>
  <id_info>
    <org_study_id>205.372</org_study_id>
    <secondary_id>2006-001009-27</secondary_id>
    <nct_id>NCT00387088</nct_id>
  </id_info>
  <brief_title>Tiotropium / Respimat One Year Study in COPD.</brief_title>
  <official_title>Efficacy {FEV1, COPD Exacerbations &amp; HRQoL} &amp; Safety of 5mcg Tiotropium Respimat in COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the long-term (one year) efficacy and safety of
      tiotropium delivered by the Respimat inhaler in patients with COPD. Specifically, the study
      will examine the effect of treatment on COPD exacerbations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 337</measure>
    <time_frame>Baseline and Day 337</time_frame>
    <description>Trough FEV1 is defined as the FEV1 measured at the -10 min time point at the end of the dosing interval (24 h post drug administration).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</measure>
    <time_frame>During actual study treatment period (planned Day 1 to Day 337)</time_frame>
    <description>Time to first COPD exacerbation (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment). Time is days from start of study treatment to onset of exacerbation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 29</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Trough FEV1 is the mean volume of air that can be forced out in one second after taking a deep breath approximately 24 hours after the last administration of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 169</measure>
    <time_frame>Baseline and Day 169</time_frame>
    <description>Trough FEV1 is the mean volume of air that can be forced out in one second after taking a deep breath approximately 24 hours after the last administration of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of COPD Exacerbations Per Patient - Exposure Adjusted</measure>
    <time_frame>During actual study treatment period (planned Day 1 to Day 337)</time_frame>
    <description>Number of COPD exacerbations (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient adjusted by length of treatment exposure (i.e. number of exacerbations multiplied by 365.25 and then divided by days of treatment exposure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of COPD Exacerbations Per Patient - naïve Estimate</measure>
    <time_frame>During actual study treatment period (planned Day 1 to Day 337)</time_frame>
    <description>Number of COPD exacerbations (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient not adjusted for treatment exposure (i.e. naïve estimate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With at Least One COPD Exacerbation</measure>
    <time_frame>During actual study treatment period (planned Day 1 to Day 337)</time_frame>
    <description>Number of patients with at least one COPD exacerbation (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Hospitalisation for COPD Exacerbation</measure>
    <time_frame>During actual study treatment period (planned Day 1 to Day 337)</time_frame>
    <description>Time to first hospitalisation for COPD exacerbation (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment). Time is days from start of study treatment to onset of exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalisations for COPD Exacerbations Per Patient - Exposure Adjusted</measure>
    <time_frame>During actual study treatment period (planned Day 1 to Day 337)</time_frame>
    <description>Number of hospitalisations for COPD exacerbations (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient adjusted by length of treatment exposure (i.e. no. of exacerbations multiplied by 365.25 and then divided by days of treatment exposure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalisations for COPD Exacerbations Per Patient - naïve Estimate</measure>
    <time_frame>During actual study treatment period (planned Day 1 to Day 337)</time_frame>
    <description>Number of hospitalisations for COPD exacerbations (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient not adjusted for treatment exposure (i.e. naïve estimate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With at Least One Hospitalisation for a COPD Exacerbation</measure>
    <time_frame>During actual study treatment period (planned Day 1 to Day 337)</time_frame>
    <description>Number of patients with at least one hospitalisation for a COPD exacerbation (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 337</measure>
    <time_frame>Baseline and Day 337</time_frame>
    <description>The SGRQ total score measures quality of life on a continuous scale ranging from 0=best state to 100=worst state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 169</measure>
    <time_frame>Baseline and Day 169</time_frame>
    <description>The SGRQ total score measures quality of life on a continuous scale ranging from 0=best state to 100=worst state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Domain Score at Day 337</measure>
    <time_frame>Baseline and Day 337</time_frame>
    <description>The SGRQ domain score (symptom, activity and impact) measures quality of life on a continuous scale ranging from 0=best state to 100=worst state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Domain Score at Day 169</measure>
    <time_frame>Baseline and Day 169</time_frame>
    <description>The SGRQ domain score (symptom, activity and impact) measures quality of life on a continuous scale ranging from 0=best state to 100=worst state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 29</measure>
    <time_frame>Baseline and Day 29</time_frame>
    <description>Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 169</measure>
    <time_frame>Baseline and Day 169</time_frame>
    <description>Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 337</measure>
    <time_frame>Baseline and Day 337</time_frame>
    <description>Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Marked Changes From Baseline in Vital Signs at End of Treatment</measure>
    <time_frame>Baseline and end of treatment</time_frame>
    <description>Marked changes from baseline in vital signs (diastolic and systolic blood pressure (DBP and SBP) and pulse rate (PR)) at end of treatment.
SBP - Increase means SBP &gt;150 mmHg and an increase above baseline of &gt;25 mmHg. SBP - Decrease means SBP &lt;100 mmHg and a decrease below baseline of &gt;10 mmHg.
DBP - Increase means DBP &gt;90 mmHg and an increase above baseline of &gt;10 mmHg. DBP - Decrease means DBP &lt;60 mmHg and a decrease below baseline of &gt;10 mmHg.
PR - Increase means PR &gt;100 bpm and an increase above baseline of &gt;10 bpm. PR - Decrease means PR &lt;60 bpm and a decrease below baseline of &gt;10 bpm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Relevant Findings in Physical Examination and ECG</measure>
    <time_frame>End of treatment</time_frame>
    <description>Clinically relevant findings in Physical Examination and ECG at end of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3991</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respimat</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <arm_group_label>Tiotropium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female

          2. At least 40 years old

          3. Smoker or ex-smoker

          4. Smoking history &gt; 10 pack-years

          5. Forced Expiratory Volume in 1 Second (FEV1) &lt; 60% predicted

        Exclusion Criteria:

          1. Recent history of myocardial infarction, life-threatening cardiac arrhythmia or
             hospitalisation for cardiac failure

          2. History of asthma or allergic conditions.

          3. Malignancy requiring treatment within past 5 years

          4. Life-threatening pulmonary obstruction, cystic fibrosis or clinically evident
             bronchiectasis

          5. Known active tuberculosis

          6. Known hypersensitivity to anticholinergic drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>205.372.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01066 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01069 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calhoun</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01043 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biddeford</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01067 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elizabeth City</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01068 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Swathmore</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01065 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.01064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.61002 Woolcock Institute of Medical Research</name>
      <address>
        <city>Glebe</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.61009 Thoracic &amp; General Physician</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.61005 Redcliffe Hospital</name>
      <address>
        <city>Redcliffe</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.61006 The Investigator Clinic</name>
      <address>
        <city>Port Lincoln</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.61007 The Burnside War Memorial Hospital</name>
      <address>
        <city>Toorak Gardens</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.61004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.61010 Ecru</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.61008 Geelong Clinical Research Centre</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.61001 Emeritus Research</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.61003 Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.55012 Universidade Federal de Santa Catarina</name>
      <address>
        <city>Florianópolis</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.55009 Hospital das Clínicas de Goiânia</name>
      <address>
        <city>Goiânia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.55005 Hospital Geral Otávio de Freitas</name>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.55001 INCOR e Hospital das Clínicas da Universidade de São Paulo</name>
      <address>
        <city>São Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.55010 Unidade de Coracao e Pulmao do Dto. de Medicina</name>
      <address>
        <city>São Paulo - SP</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.55011 CEDOES - Diagnóstico e Pesquisa</name>
      <address>
        <city>Vitória</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11007 Heritage Medical Research Building</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11013 Calgary West Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11011 Hermitage Medicentre</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11020 Wetaskiwin Lung Laboratory</name>
      <address>
        <city>Wetaskiwin</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11010 Dr. Kay Ho</name>
      <address>
        <city>Chilliwack</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11018 Pacific Lung Health Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11005 Professional Corp. Respirology</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11009 White Hills Medical Clinic</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11012 West Lincoln Memorial Hospital</name>
      <address>
        <city>Grimsby</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11014 Dr. Robert Luton</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11001 Niagara Clinical Research</name>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11019 Allergy and Asthma Research Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11003 London Road Diagnostic Clinic and Medical Centre</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11016 London Road Diagnostic Clinic and Medical Centre</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11002 Centenary Respiratory Research Associates</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11006 Clinique de médecine familiale de La Malbaie</name>
      <address>
        <city>La Malbaie</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11004 Mount Royal Family Physicians</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.11015 Dr. Arun Nayar</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.86003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.86004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.86009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chengdu, Sichuan Province</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.86008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.86001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.86010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.86011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.86012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.86005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.86006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.86007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.45004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.45005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Horsens</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.45003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odense C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.45006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.35804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.35802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jyväskylä</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.35803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3318A Clinique du Parc</name>
      <address>
        <city>Castelnau le Lez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3318B Clinique du Parc</name>
      <address>
        <city>Castelnau le Lez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3304A Cabinet Médical</name>
      <address>
        <city>Chamalières</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3301A Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont Ferrand cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3310A Centre Hospitalier</name>
      <address>
        <city>Denain</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3314A Cabinet Médical</name>
      <address>
        <city>Grasse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3306A Hôpital Ambroise Paré</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3303A Hôpital Notre Dame de Bon Secours</name>
      <address>
        <city>Metz cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3303B Hôpital Notre Dame de Bon Secours</name>
      <address>
        <city>Metz cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3312A Cabinet Médical</name>
      <address>
        <city>Montigny les Metz</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3312B Cabinet Médical</name>
      <address>
        <city>Montigny les Metz</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3302A Centre Médical Erdre Saint Augustin</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3305A Cabinet Médical</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3305B Cabinet Médical</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3315B Hôpital Caremeau</name>
      <address>
        <city>Nimes cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3315A Hôpital Caremeau</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3317A Cabinet de Pneumologie</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3320A Polyclinique Les Fleurs</name>
      <address>
        <city>Ollioules</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3320B Polyclinique Les Fleurs</name>
      <address>
        <city>Ollioules</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3316A Clinique les Bleuets</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3316B Clinique les Bleuets</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3319A Institut Arnault Tzanck</name>
      <address>
        <city>Saint Laurent du Var</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3325A Cabinet Médical</name>
      <address>
        <city>Six Four les Plages</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3321A Centre Hospitalier</name>
      <address>
        <city>St Gaudens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3321C Centre Hospitalier</name>
      <address>
        <city>St Gaudens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3324A Cabinet Médical</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3309A Cabinet médical</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.3309B Cabinet médical</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.49013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruchsal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gelnhausen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gütersloh</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.49014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.49016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Weinheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.49015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Weyhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wiesloch</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.30001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.30002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.30003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.30013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.30015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.30009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heraklion-Crete</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.30007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kalamaria</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.30005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kavala</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.30004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Komotini</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.30011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Korinthos</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.30019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nafplio</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.30008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Serres</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.30006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.30017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.30014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thiva</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.85203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.85201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.36005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erd</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.36006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mosonmagyarovar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.36007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sopron</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.91005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Andhra Pradesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.91016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Andhra Pradesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.91003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.91006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.91017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calicut,Kerala</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.91007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.91010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.91002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.91009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gujarat</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.91011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>indore,MP</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.91012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.91004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.91008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.91015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.91014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Punjab</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.91013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tamil Nadu</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.91001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uttar Pradesh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.35303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mullingar</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.39007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bussolengo (vr)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.39012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.39003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.39004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.39005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.39008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.39009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orbassano (to)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.39001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.39010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pordenone</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.39002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Prato (fi)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.39011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.39006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.82010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.82005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.82009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daejoen</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.82003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.82008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jeonbuk</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.82007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.82002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.82001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.82004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.82006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.37001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.37003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.37002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.60007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johor Baharu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.60004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kelantan Darul Naim</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.60005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.60006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.60002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kuching, Sarawak</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.60003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Penang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.60001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Selangor</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.52018 Hospital Universitario de Chihuahua</name>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.52017 Instituto Nacional de Enfermedades Respiratorias (INER)</name>
      <address>
        <city>Col. Seccion XVI</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.52013 Sanatorio Henri Dunant</name>
      <address>
        <city>Cuernavaca, Mor. México</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.52009 Hospital Civil Antiguo</name>
      <address>
        <city>Guadalajara Jal.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.52005 Hospital Civil Nuevo de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.52001 Hospital General del Estado de Sonora</name>
      <address>
        <city>Hermosillo, Sonora</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.52014 Hospital Angeles de las Lomas</name>
      <address>
        <city>Huixquilucan Edo.Mex.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.52004 Clínica de Mérida</name>
      <address>
        <city>Merida Yuc.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.52016 Hospital General de Mexicali</name>
      <address>
        <city>Mexicali Baja California Norte</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.52002 Unidad de Investigación clínica en Medicina</name>
      <address>
        <city>Monterrey, Nuevo León</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.52006 Hospital Universitario</name>
      <address>
        <city>Monterrey, Nuevo León</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.52010 Hospital General Agustin O´Haran</name>
      <address>
        <city>Mérida Yucatán</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.52012 Hospital de Nuestra Señora de la Salud</name>
      <address>
        <city>San Luis Potosi</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.52003 Hospital &quot;Angel Leaño&quot;</name>
      <address>
        <city>Zapopan, Jal.</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.31009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.31006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Drachten</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.31011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.31007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.31004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Roosendaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sneek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.31012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Voorburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.31008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Weerselo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.31005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winschoten</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sandvika</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.47003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.47002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.35102 Hospital Fernando Fonseca</name>
      <address>
        <city>Amadora</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.35101 Hospital Pulido Valente</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.35104 Hospital de Santa Marta</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.35103 Hospital de São João</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.35105 Centro Hospitalar do Alto Minho, Estrada de Santa Luzia</name>
      <address>
        <city>Viana do Castelo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.65001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.65003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.65005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.42102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.42103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nove Zamky</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.27002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bellville</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.27001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.27004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.27008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.27006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Centurion</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.27003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.27005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.27007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Somerset West</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.34005 Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.34004 Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.34006 Hospital 12 de octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.34001 Hospital Mutua Terrassa</name>
      <address>
        <city>Terrassa (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.34002 Hospital Universitario Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.46001 Björknäs Vårdcentral</name>
      <address>
        <city>Boden</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.46004 Näsets läkargrupp</name>
      <address>
        <city>Höllviken</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.46005 Lungmedicinska kliniken</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.46006 Lungmedicinska Kliniken</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.46002 Alnö Vårdcentral</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.41002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.41003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montana</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.41001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.88607 Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.88606 National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.88601 National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.88602 Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.88603 Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.88604 Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.88608 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.88609 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.88605 Chang Gung Memorial Hosp-Linkou</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.90006 Gazi Universitesi Tip Fakultesi Gogus Hastaliklari A.B.D.</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.90007 Atatürk Gög. Hastaliklari ve Cerrahisi Egitim Hastanesi</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.90003 Uludag Universitesi Tip Fakultesi Gogus Hastaliklari</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.90009 Trakya Universitesi Tip Fakultesi Gogus Hastaliklari A.B.D.</name>
      <address>
        <city>Edirne</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.90004 Dr. Lütfi Kirdar Egitim ve Arastirma Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.90005 Istanbul Universitesi Cerrahpasa Tip Fakultesi</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.90001 Izmir Tepecik Gogus Hastaliklari ve Gogus Cerrahisi Hast.</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.90008 Erciyes Universitesi Tip Fakultesi</name>
      <address>
        <city>Kayseri</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.90010 Selcuk Universitesi Tip Fakultesi</name>
      <address>
        <city>Konya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.90002 19 Mayis Universitesi Tip Fakultesi Gogus Hastaliklari A.B.D</name>
      <address>
        <city>Samsun</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aston Clinton, Aylesbury</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Carmarthen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chertsey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Darlington</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>East Horsley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fowey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frome</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenisland</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heywood</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Isleworth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kirkby in Ashfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mortimer</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Penzance</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sneinton, Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St Just, Penzance</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Austell</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sunderland</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wellingborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westbury on Trym</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Windsor</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.372.44019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Woking</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2006</study_first_submitted>
  <study_first_submitted_qc>October 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2006</study_first_posted>
  <results_first_submitted>November 13, 2009</results_first_submitted>
  <results_first_submitted_qc>December 18, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 22, 2010</results_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tiotropium</title>
          <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1989"/>
                <participants group_id="P2" count="2002"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1671"/>
                <participants group_id="P2" count="1629"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="318"/>
                <participants group_id="P2" count="373"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="156"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tiotropium</title>
          <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1952"/>
            <count group_id="B2" value="1965"/>
            <count group_id="B3" value="3917"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The TS was made up of all randomised and treated participants excluding 74 patients with potential fraudulent data from one investigator site</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.8" spread="9.1"/>
                    <measurement group_id="B2" value="64.8" spread="9"/>
                    <measurement group_id="B3" value="64.80" spread="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>The TS was made up of all randomised and treated participants excluding 74 patients with potential fraudulent data from one investigator site</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="428"/>
                    <measurement group_id="B2" value="452"/>
                    <measurement group_id="B3" value="880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1524"/>
                    <measurement group_id="B2" value="1513"/>
                    <measurement group_id="B3" value="3037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 337</title>
        <description>Trough FEV1 is defined as the FEV1 measured at the -10 min time point at the end of the dosing interval (24 h post drug administration).</description>
        <time_frame>Baseline and Day 337</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. 133 participants from the FAS were excluded due to insufficient FEV1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 337</title>
          <description>Trough FEV1 is defined as the FEV1 measured at the -10 min time point at the end of the dosing interval (24 h post drug administration).</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. 133 participants from the FAS were excluded due to insufficient FEV1 data.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1889"/>
                <count group_id="O2" value="1870"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.119" spread="0.007"/>
                    <measurement group_id="O2" value="0.018" spread="0.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with pooled centre, LABA use, and treatment fitted as main effects and the baseline trough FEV1 as a covariate.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.102</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.009</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.085</ci_lower_limit>
            <ci_upper_limit>0.118</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
        <description>Time to first COPD exacerbation (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment). Time is days from start of study treatment to onset of exacerbation.</description>
        <time_frame>During actual study treatment period (planned Day 1 to Day 337)</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation</title>
          <description>Time to first COPD exacerbation (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment). Time is days from start of study treatment to onset of exacerbation.</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1939"/>
                <count group_id="O2" value="1953"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">As &lt;50% of the patients experienced an exacerbation in both treatment groups the median and 95% confidence interval were not estimable. Refer to the secondary endpoint 'Number of patients with at least one COPD exacerbation' for further information.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="354.0">As &lt;50% of the patients experienced an exacerbation in both treatment groups the median and 95% confidence interval were not estimable. Refer to the secondary endpoint 'Number of patients with at least one COPD exacerbation' for further information.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 29</title>
        <description>Trough FEV1 is the mean volume of air that can be forced out in one second after taking a deep breath approximately 24 hours after the last administration of study drug.</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. 147 participants from the FAS were excluded due to insufficient FEV1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 29</title>
          <description>Trough FEV1 is the mean volume of air that can be forced out in one second after taking a deep breath approximately 24 hours after the last administration of study drug.</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. 147 participants from the FAS were excluded due to insufficient FEV1 data.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1879"/>
                <count group_id="O2" value="1866"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.005"/>
                    <measurement group_id="O2" value="0.017" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 169</title>
        <description>Trough FEV1 is the mean volume of air that can be forced out in one second after taking a deep breath approximately 24 hours after the last administration of study drug.</description>
        <time_frame>Baseline and Day 169</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. 133 participants from the FAS were excluded due to insufficient FEV1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 169</title>
          <description>Trough FEV1 is the mean volume of air that can be forced out in one second after taking a deep breath approximately 24 hours after the last administration of study drug.</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. 133 participants from the FAS were excluded due to insufficient FEV1 data.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1889"/>
                <count group_id="O2" value="1870"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.121" spread="0.006"/>
                    <measurement group_id="O2" value="0.018" spread="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of COPD Exacerbations Per Patient - Exposure Adjusted</title>
        <description>Number of COPD exacerbations (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient adjusted by length of treatment exposure (i.e. number of exacerbations multiplied by 365.25 and then divided by days of treatment exposure)</description>
        <time_frame>During actual study treatment period (planned Day 1 to Day 337)</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of COPD Exacerbations Per Patient - Exposure Adjusted</title>
          <description>Number of COPD exacerbations (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient adjusted by length of treatment exposure (i.e. number of exacerbations multiplied by 365.25 and then divided by days of treatment exposure)</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data.</population>
          <units>COPD exacerbations per year</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1939"/>
                <count group_id="O2" value="1953"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0" lower_limit="0" upper_limit="21.5"/>
                    <measurement group_id="O2" value="0" spread="0" lower_limit="0" upper_limit="182.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of COPD Exacerbations Per Patient - naïve Estimate</title>
        <description>Number of COPD exacerbations (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient not adjusted for treatment exposure (i.e. naïve estimate)</description>
        <time_frame>During actual study treatment period (planned Day 1 to Day 337)</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of COPD Exacerbations Per Patient - naïve Estimate</title>
          <description>Number of COPD exacerbations (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient not adjusted for treatment exposure (i.e. naïve estimate)</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data.</population>
          <units>COPD exacerbations</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1939"/>
                <count group_id="O2" value="1953"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="0" spread="0" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With at Least One COPD Exacerbation</title>
        <description>Number of patients with at least one COPD exacerbation (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment)</description>
        <time_frame>During actual study treatment period (planned Day 1 to Day 337)</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least One COPD Exacerbation</title>
          <description>Number of patients with at least one COPD exacerbation (defined as a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment)</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1939"/>
                <count group_id="O2" value="1953"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="685"/>
                    <measurement group_id="O2" value="842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Hospitalisation for COPD Exacerbation</title>
        <description>Time to first hospitalisation for COPD exacerbation (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment). Time is days from start of study treatment to onset of exacerbation</description>
        <time_frame>During actual study treatment period (planned Day 1 to Day 337)</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Hospitalisation for COPD Exacerbation</title>
          <description>Time to first hospitalisation for COPD exacerbation (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment). Time is days from start of study treatment to onset of exacerbation</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1939"/>
                <count group_id="O2" value="1953"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">As &lt;50% of the patients experienced an exacerbation in both treatment groups the median and 95% confidence interval were not estimable. Refer to the secondary endpoint 'Number of patients with at least one COPD exacerbation' for further information.</measurement>
                    <measurement group_id="O2" value="NA">As &lt;50% of the patients experienced an exacerbation in both treatment groups the median and 95% confidence interval were not estimable. Refer to the secondary endpoint 'Number of patients with at least one COPD exacerbation' for further information.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospitalisations for COPD Exacerbations Per Patient - Exposure Adjusted</title>
        <description>Number of hospitalisations for COPD exacerbations (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient adjusted by length of treatment exposure (i.e. no. of exacerbations multiplied by 365.25 and then divided by days of treatment exposure)</description>
        <time_frame>During actual study treatment period (planned Day 1 to Day 337)</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospitalisations for COPD Exacerbations Per Patient - Exposure Adjusted</title>
          <description>Number of hospitalisations for COPD exacerbations (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient adjusted by length of treatment exposure (i.e. no. of exacerbations multiplied by 365.25 and then divided by days of treatment exposure)</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data.</population>
          <units>hospitalisations for COPD exacerbations</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1939"/>
                <count group_id="O2" value="1953"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0" lower_limit="0" upper_limit="21.5"/>
                    <measurement group_id="O2" value="0" spread="0" lower_limit="0" upper_limit="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospitalisations for COPD Exacerbations Per Patient - naïve Estimate</title>
        <description>Number of hospitalisations for COPD exacerbations (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient not adjusted for treatment exposure (i.e. naïve estimate)</description>
        <time_frame>During actual study treatment period (planned Day 1 to Day 337)</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospitalisations for COPD Exacerbations Per Patient - naïve Estimate</title>
          <description>Number of hospitalisations for COPD exacerbations (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment) per patient not adjusted for treatment exposure (i.e. naïve estimate)</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data.</population>
          <units>hospitalisations for COPD exacerbations</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1939"/>
                <count group_id="O2" value="1953"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="0" spread="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With at Least One Hospitalisation for a COPD Exacerbation</title>
        <description>Number of patients with at least one hospitalisation for a COPD exacerbation (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment)</description>
        <time_frame>During actual study treatment period (planned Day 1 to Day 337)</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least One Hospitalisation for a COPD Exacerbation</title>
          <description>Number of patients with at least one hospitalisation for a COPD exacerbation (a complex of respiratory events/symptoms (increase or new onset) with a duration of 3 days or more requiring a change in treatment)</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1939"/>
                <count group_id="O2" value="1953"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 337</title>
        <description>The SGRQ total score measures quality of life on a continuous scale ranging from 0=best state to 100=worst state</description>
        <time_frame>Baseline and Day 337</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. 534 participants from the FAS were excluded due to insufficient SGRQ data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 337</title>
          <description>The SGRQ total score measures quality of life on a continuous scale ranging from 0=best state to 100=worst state</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. 534 participants from the FAS were excluded due to insufficient SGRQ data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1690"/>
                <count group_id="O2" value="1668"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.726" spread="0.372"/>
                    <measurement group_id="O2" value="-1.787" spread="0.374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 169</title>
        <description>The SGRQ total score measures quality of life on a continuous scale ranging from 0=best state to 100=worst state</description>
        <time_frame>Baseline and Day 169</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. 534 participants from the FAS were excluded due to insufficient SGRQ data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at Day 169</title>
          <description>The SGRQ total score measures quality of life on a continuous scale ranging from 0=best state to 100=worst state</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. 534 participants from the FAS were excluded due to insufficient SGRQ data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1690"/>
                <count group_id="O2" value="1668"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.764" spread="0.348"/>
                    <measurement group_id="O2" value="-2.568" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Domain Score at Day 337</title>
        <description>The SGRQ domain score (symptom, activity and impact) measures quality of life on a continuous scale ranging from 0=best state to 100=worst state</description>
        <time_frame>Baseline and Day 337</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. Up to 534 participants from the FAS were excluded due to insufficient SGRQ data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Domain Score at Day 337</title>
          <description>The SGRQ domain score (symptom, activity and impact) measures quality of life on a continuous scale ranging from 0=best state to 100=worst state</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. Up to 534 participants from the FAS were excluded due to insufficient SGRQ data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1939"/>
                <count group_id="O2" value="1953"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptoms (N=1704,1688)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.260" spread="0.546"/>
                    <measurement group_id="O2" value="-3.307" spread="0.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (N=1690,1668)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.196" spread="0.456"/>
                    <measurement group_id="O2" value="-0.226" spread="0.460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impacts (N=1690,1668)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.873" spread="0.409"/>
                    <measurement group_id="O2" value="-2.038" spread="0.412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Domain Score at Day 169</title>
        <description>The SGRQ domain score (symptom, activity and impact) measures quality of life on a continuous scale ranging from 0=best state to 100=worst state</description>
        <time_frame>Baseline and Day 169</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. Up to 534 participants from the FAS were excluded due to insufficient SGRQ data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Domain Score at Day 169</title>
          <description>The SGRQ domain score (symptom, activity and impact) measures quality of life on a continuous scale ranging from 0=best state to 100=worst state</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. Up to 534 participants from the FAS were excluded due to insufficient SGRQ data.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1939"/>
                <count group_id="O2" value="1953"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptoms (N=1704,1688)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.555" spread="0.530"/>
                    <measurement group_id="O2" value="-3.268" spread="0.532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activities (N=1690,1668)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.573" spread="0.432"/>
                    <measurement group_id="O2" value="-1.218" spread="0.435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impacts (N=1690,1668)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.917" spread="0.390"/>
                    <measurement group_id="O2" value="-2.935" spread="0.392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 29</title>
        <description>Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.</description>
        <time_frame>Baseline and Day 29</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. 147 participants from the FAS were excluded due to insufficient FVC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 29</title>
          <description>Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. 147 participants from the FAS were excluded due to insufficient FVC data.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1879"/>
                <count group_id="O2" value="1866"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.176" spread="0.009"/>
                    <measurement group_id="O2" value="0.025" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 169</title>
        <description>Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.</description>
        <time_frame>Baseline and Day 169</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. 133 participants from the FAS were excluded due to insufficient FVC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 169</title>
          <description>Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. 133 participants from the FAS were excluded due to insufficient FVC data.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1889"/>
                <count group_id="O2" value="1870"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.179" spread="0.010"/>
                    <measurement group_id="O2" value="0.019" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 337</title>
        <description>Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.</description>
        <time_frame>Baseline and Day 337</time_frame>
        <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. 133 participants from the FAS were excluded due to insufficient FVC data.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Forced Vital Capacity (FVC) at Day 337</title>
          <description>Trough FVC is the mean maximum volume of air that can be forcibly expired from the lungs; measured approximately 24 hours after the last administration of study drug.</description>
          <population>The FAS was made up of all randomised and treated participants excluding 99 patients with questionable data. 133 participants from the FAS were excluded due to insufficient FVC data.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1889"/>
                <count group_id="O2" value="1870"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.168" spread="0.011"/>
                    <measurement group_id="O2" value="-0.001" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Marked Changes From Baseline in Vital Signs at End of Treatment</title>
        <description>Marked changes from baseline in vital signs (diastolic and systolic blood pressure (DBP and SBP) and pulse rate (PR)) at end of treatment.
SBP - Increase means SBP &gt;150 mmHg and an increase above baseline of &gt;25 mmHg. SBP - Decrease means SBP &lt;100 mmHg and a decrease below baseline of &gt;10 mmHg.
DBP - Increase means DBP &gt;90 mmHg and an increase above baseline of &gt;10 mmHg. DBP - Decrease means DBP &lt;60 mmHg and a decrease below baseline of &gt;10 mmHg.
PR - Increase means PR &gt;100 bpm and an increase above baseline of &gt;10 bpm. PR - Decrease means PR &lt;60 bpm and a decrease below baseline of &gt;10 bpm.</description>
        <time_frame>Baseline and end of treatment</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Marked Changes From Baseline in Vital Signs at End of Treatment</title>
          <description>Marked changes from baseline in vital signs (diastolic and systolic blood pressure (DBP and SBP) and pulse rate (PR)) at end of treatment.
SBP - Increase means SBP &gt;150 mmHg and an increase above baseline of &gt;25 mmHg. SBP - Decrease means SBP &lt;100 mmHg and a decrease below baseline of &gt;10 mmHg.
DBP - Increase means DBP &gt;90 mmHg and an increase above baseline of &gt;10 mmHg. DBP - Decrease means DBP &lt;60 mmHg and a decrease below baseline of &gt;10 mmHg.
PR - Increase means PR &gt;100 bpm and an increase above baseline of &gt;10 bpm. PR - Decrease means PR &lt;60 bpm and a decrease below baseline of &gt;10 bpm.</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1747"/>
                <count group_id="O2" value="1749"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP - Increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP - Decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP - Increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP - Decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR - Increase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR - Decrease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Relevant Findings in Physical Examination and ECG</title>
        <description>Clinically relevant findings in Physical Examination and ECG at end of treatment</description>
        <time_frame>End of treatment</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Relevant Findings in Physical Examination and ECG</title>
          <description>Clinically relevant findings in Physical Examination and ECG at end of treatment</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1952"/>
                <count group_id="O2" value="1965"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phys. Exam - No new/worsened finding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1723"/>
                    <measurement group_id="O2" value="1733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phys. Exam - new or worsened finding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phys. Exam - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                    <measurement group_id="O2" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG - No new/worsened finding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1674"/>
                    <measurement group_id="O2" value="1677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG - new or worsened finding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG - Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241"/>
                    <measurement group_id="O2" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 30 days after last drug administration.</time_frame>
      <desc>74 patients were excluded from the treated set due to potential fraudulent data from one investigator site</desc>
      <group_list>
        <group group_id="E1">
          <title>Tiotropium</title>
          <description>Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="342" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="336" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cor pulmonale acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Tricuspid valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Chilaiditi's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Enterocutaneous fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Proctocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Drug interaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pitting oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cholecysititis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cholecysititis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Epiglottitis haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Urinary tract infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Blood alcohol increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Chest x-ray abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Facet joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myelomonocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Benigh neoplasm of bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Bone cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Metastases to skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cerebral circulatory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cerebral thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (11.1)">Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Urethral meatus stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Prostatic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="155" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pulmonary fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lichen nitidus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Living in residential institution</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Gallbladder operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Ileostomy closure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Shoulder arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Urethrotomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Aortic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="866" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="926" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="561" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="659" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="1965"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="1952"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="1965"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Pharmaceuticals</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

